These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 24722313)

  • 41. Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: Comparison of intraindividually matched T1 - and T2 (*) -based bolus techniques.
    Bonekamp D; Deike K; Wiestler B; Wick W; Bendszus M; Radbruch A; Heiland S
    J Magn Reson Imaging; 2015 Jul; 42(1):87-96. PubMed ID: 25244574
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnostic utility of intravoxel incoherent motion mr imaging in differentiating primary central nervous system lymphoma from glioblastoma multiforme.
    Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Kitamura Y; Mizoguchi M; Yoshimoto K; Kuga D; Suzuki SO; Baba S; Isoda T; Iwaki T; Iihara K; Honda H
    J Magn Reson Imaging; 2016 Nov; 44(5):1256-1261. PubMed ID: 27093558
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dynamic contrast enhanced MRI in the differential diagnosis of adrenal adenomas and malignant adrenal masses.
    Inan N; Arslan A; Akansel G; Anik Y; Balci NC; Demirci A
    Eur J Radiol; 2008 Jan; 65(1):154-62. PubMed ID: 17466481
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differentiation between orbital malignant and benign tumors using intravoxel incoherent motion diffusion-weighted imaging: Correlation with dynamic contrast-enhanced magnetic resonance imaging.
    Xu XQ; Hu H; Su GY; Liu H; Wu FY; Shi HB
    Medicine (Baltimore); 2019 Mar; 98(12):e14897. PubMed ID: 30896639
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma.
    Hatzoglou V; Oh JH; Buck O; Lin X; Lee M; Shukla-Dave A; Young RJ; Peck KK; Vachha B; Holodny AI; Grommes C
    J Neurooncol; 2018 Nov; 140(2):351-358. PubMed ID: 30073640
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
    Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
    Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
    Yun TJ; Park CK; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Choi SH
    Radiology; 2015 Mar; 274(3):830-40. PubMed ID: 25333475
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discrimination between Glioblastoma and Solitary Brain Metastasis: Comparison of Inflow-Based Vascular-Space-Occupancy and Dynamic Susceptibility Contrast MR Imaging.
    Li X; Wang D; Liao S; Guo L; Xiao X; Liu X; Xu Y; Hua J; Pillai JJ; Wu Y
    AJNR Am J Neuroradiol; 2020 Apr; 41(4):583-590. PubMed ID: 32139428
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Primary central nervous system lymphoma and atypical glioblastoma: Differentiation using radiomics approach.
    Suh HB; Choi YS; Bae S; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
    Eur Radiol; 2018 Sep; 28(9):3832-3839. PubMed ID: 29626238
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Correlation of Preoperative Von Willebrand Factor with Magnetic Resonance Imaging Perfusion and Permeability Parameters as Predictors of Prognosis in Glioblastoma.
    Navone SE; Doniselli FM; Summers P; Guarnaccia L; Rampini P; Locatelli M; Campanella R; Marfia G; Costa A
    World Neurosurg; 2019 Feb; 122():e226-e234. PubMed ID: 30312827
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Application of Dynamic Contrast-Enhanced MRI Parameters for Differentiating Squamous Cell Carcinoma and Malignant Lymphoma of the Oropharynx.
    Park M; Kim J; Choi YS; Lee SK; Koh YW; Kim SH; Choi EC
    AJR Am J Roentgenol; 2016 Feb; 206(2):401-7. PubMed ID: 26797371
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility.
    Kim HS; Goh MJ; Kim N; Choi CG; Kim SJ; Kim JH
    Radiology; 2014 Dec; 273(3):831-43. PubMed ID: 24885857
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differentiation between primary CNS lymphoma and glioblastoma: qualitative and quantitative analysis using arterial spin labeling MR imaging.
    You SH; Yun TJ; Choi HJ; Yoo RE; Kang KM; Choi SH; Kim JH; Sohn CH
    Eur Radiol; 2018 Sep; 28(9):3801-3810. PubMed ID: 29619520
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differentiating Atypical Hemangiomas and Metastatic Vertebral Lesions: The Role of T1-Weighted Dynamic Contrast-Enhanced MRI.
    Morales KA; Arevalo-Perez J; Peck KK; Holodny AI; Lis E; Karimi S
    AJNR Am J Neuroradiol; 2018 May; 39(5):968-973. PubMed ID: 29650780
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In Vivo DCE-MRI for the Discrimination Between Glioblastoma and Radiation Necrosis in Rats.
    Bolcaen J; Descamps B; Acou M; Deblaere K; den Broecke CV; Boterberg T; Vanhove C; Goethals I
    Mol Imaging Biol; 2017 Dec; 19(6):857-866. PubMed ID: 28303489
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
    Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
    PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differentiation of Enhancing Glioma and Primary Central Nervous System Lymphoma by Texture-Based Machine Learning.
    Alcaide-Leon P; Dufort P; Geraldo AF; Alshafai L; Maralani PJ; Spears J; Bharatha A
    AJNR Am J Neuroradiol; 2017 Jun; 38(6):1145-1150. PubMed ID: 28450433
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison between perfusion computed tomography and dynamic contrast-enhanced magnetic resonance imaging in assessing glioblastoma microvasculature.
    Jia ZZ; Shi W; Shi JL; Shen DD; Gu HM; Zhou XJ
    Eur J Radiol; 2017 Feb; 87():120-124. PubMed ID: 28034567
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative study of methods for determining vascular permeability and blood volume in human gliomas.
    Harrer JU; Parker GJ; Haroon HA; Buckley DL; Embelton K; Roberts C; Balériaux D; Jackson A
    J Magn Reson Imaging; 2004 Nov; 20(5):748-57. PubMed ID: 15503330
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differentiation of malignant from benign pheochromocytomas with diffusion-weighted and dynamic contrast-enhanced magnetic resonance at 3.0 T.
    Dong Y; Liu Q
    J Comput Assist Tomogr; 2012; 36(4):361-6. PubMed ID: 22805661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.